文献速递乳腺癌放疗

MA.20试验:预测乳腺癌腋窝手术与放疗后淋巴水肿的列线图开发与验证

Development and Validation of a Nomogram to Predict Lymphedema After Axillary Surgery and Radiation Therapy in Women With Breast Cancer From the NCIC CTG MA.20 Randomized Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-05-11

基于MA.20随机试验1832例乳腺癌患者数据,开发预测腋窝手术及放疗后≥2级淋巴水肿的列线图,识别BMI、腋窝手术范围及区域淋巴结照射范围为预测因子,内部验证C指数0.69,外部验证(N=785)C指数0.71。

要点

  • BMI每增加1单位,淋巴水肿风险 adjusted OR 1.05(95%CI 1.03-1.08,P<.001)。
  • 腋窝手术切除淋巴结数8-11、12-15、≥16枚的 adjusted OR 分别为3.28、4.04、5.08。
  • 区域淋巴结照射范围有限和广泛的 adjusted OR 分别为1.66和2.31。

核心结论

  • 基于MA.20随机试验临床数据构建的列线图可较准确预测乳腺癌腋窝手术及放疗后淋巴水肿风险,或可用于筛查和风险分层。

研究设计与样本

  • 利用MA.20试验2000年3月至2007年2月入组的1832例女性数据构建预后模型,主要终点为NCI CTC v2.0≥2级淋巴水肿。
  • 采用多变量逻辑回归估计模型性能,并在单一大规模学术癌症中心785例数据中进行外部验证。

主要发现

  • MA.20队列中,BMI(adjusted OR 1.05/单位,95%CI 1.03-1.08,P<.001)、腋窝手术范围(8-11枚 adjusted OR 3.28,95%CI 1.53-7.89,P=.004;12-15枚 adjusted OR 4.04,95%CI 1.76-10.26,P=.002;≥16枚 adjusted OR 5.08,95%CI 2.26-12.70,P<.001)及淋巴结照射范围(有限 adjusted OR 1.66,95%CI 1.08-2.56,P=.02;广泛 adjusted OR 2.31,95%CI 1.28-4.10,P=.004)为淋巴水肿预测因子。
  • 列线图内部验证一致性指数0.69(95%CI 0.64-0.74),外部验证一致性指数0.71(95%CI 0.66-0.76)。

关键数值与推荐

  • 淋巴水肿主要终点定义为NCI CTC v2.0 grade 2或以上。
  • 预测因子包括BMI、腋窝手术切除淋巴结数及区域淋巴结照射范围。

临床怎么用

  • 可利用列线图基于BMI、腋窝手术范围及淋巴结照射范围对乳腺癌患者进行淋巴水肿风险分层和筛查。
  • 该工具或有助于筛选适合淋巴水肿治疗干预试验的高风险患者。

局限性

  • 外部验证仅基于单一大规模学术癌症中心数据。
  • 列线图内部和外部验证一致性指数分别为0.69和0.71,预测准确性中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Regional nodal irradiation for women with breast cancer is known to be an important risk factor for the development of upper extremity lymphedema, but tools to accurately predict lymphedema risks for individual patients are lacking. This study sought to develop and validate a nomogram to predict lymphedema risk after axillary surgery and radiation therapy in women with breast cancer. METHODS AND MATERIALS: Data from 1832 women accrued on the MA.20 trial between March 2000 and February 2007 were used to create a prognostic model with National Cancer Institute Common Toxicity Criteria Version 2.0 grade 2 or higher lymphedema as the primary endpoint. Multivariable logistic regression estimated model performance. External validation was performed on data from a single large academic cancer center (N = 785). RESULTS: In the MA.20 trial cohort, 3 risk factors were predictive of lymphedema risk: body mass index (adjusted odds ratio, 1.05 per unit body mass index; 95% confidence interval [CI], 1.03-1.08, P < .001), extent of axillary surgery (adjusted odds radio for 8-11 lymph nodes removed, 3.28 [95% CI, 1.53-7.89] P = .004; 12-15 lymph nodes, 4.04 [95% CI, 1.76-10.26] P = .002; ≥16 nodes, 5.08 [95% CI, 2.26-12.70] P < .001), and extent of nodal irradiation (adjusted odds radio for limited, 1.66 [95% CI, 1.08-2.56] P = .02; for extensive, 2.31 [95% CI, 1.28-4.10] P = .004). A nomogram was created from these data that predicted lymphedema risk with reasonable accuracy confirmed by both internal (concordance index, 0.69; 95% CI, 0.64-0.74) and external validation (concordance index, 0.71; 95% CI, 0.66-0.76). CONCLUSIONS: The nomogram created from the MA.20 randomized trial data using clinical information may be useful for lymphedema screening and risk stratification for therapeutic intervention trials.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Gross JP, Whelan TJ, Parulekar WR, et al. Development and Validation of a Nomogram to Predict Lymphedema After Axillary Surgery and Radiation Therapy in Women With Breast Cancer From the NCIC CTG MA.20 Randomized Trial. Int J Radiat Oncol Biol Phys. 2019. PMID: 31085285. doi:10.1016/j.ijrobp.2019.05.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。